Authors

Senior advisor to NextGen Invent Corporation

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences companies must navigate in this evolving landscape.

Kenneth Getz, MBA

Executive Director of the Tufts Center for the Study of Drug Development (CSDD)

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

2 years ago

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Authors

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Trending on PharmExec

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

FDA Pilot Targets Faster Early-Stage Drug Trial Starts

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

DARPA's Role in Bringing Manufacturing Back to the US

The Next Evolution of Class of Trade: Why Customer Identity Is Becoming Market Access’s Hardest Problem